Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 17/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308294 | 0.97 | AVPR1B (0.54) | AVPR1BLTB4RSMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL4308493 | 0.96 | AVPR1B (0.54) | AVPR1BSMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL4304194 | 0.90 | AVPR1B (0.52) | AVPR1BLTB4RSMN1; SMN2 | |
| SCHEMBL8020813 | 0.86 | AVPR1B (0.55) | AVPR1BSMN1; SMN2 | |
| SCHEMBL8019748 | 0.82 | AVPR1B (0.52) | AVPR1B | |
| SCHEMBL8018283 | 0.82 | AVPR1B (0.41) | AVPR1BSMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL4304919 | 0.82 | AVPR1B (0.56) | AVPR1BHCRTR1HCRTR2 | |
| SCHEMBL8010966 | 0.81 | AVPR1B (0.80) | AVPR1B | |
| SCHEMBL4304225 | 0.78 | AVPR1B (0.80) | AVPR1B | |
| SCHEMBL4302704 | 0.76 | AVPR1B (0.81) | AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009130232-A1 | PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130232-A1 | PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |